Ionis Pharmaceuticals price target raised to $43 from $38 at Stifel

Stifel raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $43 from $38 and keeps a Hold rating on the shares. The company announced the approval of Dawnzera for prophylaxis to prevent attacks of hereditary angioedema in adult and pediatric patients 12 years of age and older, with the label coming in “clean” with no major surprises and in-line with other HAE labels, the analyst tells investors in a research note. The firm added management is confident that HAE patients continue to switch prophys due to unmet need in existing options, and Dawnzera offers a compelling product profile that can drive switching.